Chen En-Qiang, Tang Hong
En-Qiang Chen, Hong Tang, Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.
World J Gastroenterol. 2014 May 21;20(19):5730-6. doi: 10.3748/wjg.v20.i19.5730.
Chronic hepatitis B (CHB) is currently medically managed with either interferon-alpha or one of the five nucleos(t)ide analogs. However, there are still a large number of CHB patients whose response to the above therapies remains less than satisfactory, and their incomplete or non-response to antiviral therapies has plagued clinicians worldwide. In recent years, a newly proposed optimization therapy has provided us with a new approach to solve this problem. The key points in this optimization therapy are to initiate antiviral therapy with an appropriate agent at the correct time point, and to adjust treatments in patients with poor early responses by adding a second agent or switching to another more potent agent. In this review, we summarize recent developments in optimization therapy for the treatment of CHB, and provide an outlook for future research in this field.
慢性乙型肝炎（CHB）目前的医学治疗方法是使用α干扰素或五种核苷（酸）类似物之一。然而，仍有大量CHB患者对上述治疗的反应不尽人意，他们对抗病毒治疗的不完全反应或无反应一直困扰着全球的临床医生。近年来，新提出的优化治疗为我们解决这一问题提供了新方法。这种优化治疗的关键点是在正确的时间点用合适的药物启动抗病毒治疗，并通过添加第二种药物或换用另一种更有效的药物来调整早期反应不佳患者的治疗方案。在本综述中，我们总结了CHB治疗优化疗法的最新进展，并对该领域未来的研究进行了展望。
